The story of Dan Markingson’s suicide while enrolled in a University of Minnesota trial of the anti-psychotic drug Seroquel is being told once again, this time on the front page of CityPages. It focuses on continued – but still unresolved – scrutiny of the head of the University’s psychiatry department, Dr. Charles Schulz. Excerpts:
“MARKINGSON’S SUICIDE HAS cast a harsh spotlight on the University of Minnesota psychiatry department. The Federal Drug Administration, the Attorney General’s Office, and the college’s Internal Review Board all wanted to know how a 26-year-old research subject ended up dead.
So did his mom. After a year of combing through studies and public records, (she) filed a malpractice suit against Schulz and the U of M, accusing them of putting Big Pharma’s bottom line ahead of her son’s mental health.
In December, a group of eight bioethicists at the U of M wrote a letter to the college’s Board of Regents, demanding the appointment of an independent board to investigate whether lapses in ethics and judgment led to Markingson’s suicide.
“This goes beyond everything and anything, and this should have brought the house down on the university,” says Vera Sharav, president of the Alliance for Human Research Protection, a patient-advocacy group. “There has to be zero tolerance, because a lot hangs on it, including lives.”
The issue will soon come to a head. The U of M has been investigating a complaint about Schulz’s connections to Big Pharma and is expected to issue the results in a matter of weeks.
“If there’s any question that the investigation was superficial, it ought to be by an independent group that can determine what the facts are,” says Jerome P. Kassirer, former editor of the New England Journal of Medicine, who is familiar with the circumstances surrounding the Markingson case. “It looks worrisome to me.”
If you haven’t heard this saga before, the CityPages >3,000-word story will give you much of the background.
Here’s a screenshot of the University’s psychiatry department’s web page.
Opinions on other issues in news, journals, PR, advertising, marketing
We’ve written about the hype of liquid biopsies for years (see link in comment below). And now this…. https://www.statnews.com/2022/01/12/medicare-shouldnt-cover-liquid-biopsies-early-cancer-detection/
Case counts still matter. “(There) are stories that may not be told adequately if only hospitalizations and deaths are emphasized.” @garyschwitzer interviewed by @dbauder of @AP. https://apnews.com/article/omicron-changing-news-outlets-covid-data-da9272f7c4c8a109c3bfb56bed9e9c76
My friend Gary @garyschwitzer wrote to his city council representative in a Minnesota town about a Viva Las Vegas event scheduled for January.
The response he got seems to perfectly capture where we are now.
https://www.healthnewsreview.org/2021/12/2021-ends-with-covid-craziness-in-sports-and-politics/
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Comments are closed.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like